Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Federal Trade Commission
Julphar
QuintilesIMS
US Department of Justice
Teva
Cerilliant
Boehringer Ingelheim
Queensland Health
Fuji

Generated: October 21, 2017

DrugPatentWatch Database Preview

VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER Drug Profile

« Back to Dashboard

What is the patent landscape for Vaprisol In 5% Dextrose In Plastic Container, and when can generic versions of Vaprisol In 5% Dextrose In Plastic Container launch?

Vaprisol In 5% Dextrose In Plastic Container is a drug marketed by Cumberland Pharms and is included in one NDA. There is one patent protecting this drug.

This drug has twenty-nine patent family members in seventeen countries.

The generic ingredient in VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER is conivaptan hydrochloride. One supplier is listed for this compound. Additional details are available on the conivaptan hydrochloride profile page.

Summary for Tradename: VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list609
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER at DailyMed

Pharmacology for Tradename: VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cumberland Pharms
VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER
conivaptan hydrochloride
INJECTABLE;IV (INFUSION)021697-002Oct 8, 2008RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,856,564 Condensed benzazepine derivative and pharmaceutical composition thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

Country Document Number Estimated Expiration
Canada2453123► Subscribe
Hungary9600102► Subscribe
World Intellectual Property Organization (WIPO)9503305► Subscribe
China1040210► Subscribe
Australia683483► Subscribe
Japan2744527► Subscribe
Norway306303► Subscribe
Poland312654► Subscribe
Finland113178► Subscribe
Russian Federation2129123► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
Julphar
US Army
Queensland Health
Colorcon
UBS
Fish and Richardson
Johnson and Johnson
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot